Payment overview · 2025
General Payments
$124.23
7 reported records · 5 companies
Healthcare provider profile · identity verified
Kelsey A Moon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1962852186
Verified facts
What the public records show
CMS Open Payments records show Kelsey A Moon, M.D. received $124.23 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 34.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.30 | 34.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.08 | 21.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.57 | 17.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.71 | 13.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.57 | 12.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $124.23 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.30 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.08 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 51 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 100 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
51 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 655 | 213 |
| Amlodipine Besylate | Amlodipine Besylate | 596 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 583 | 166 |
| Losartan Potassium | Losartan Potassium | 340 | 107 |
| Lisinopril | Lisinopril | 322 | 104 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 304 | 99 |
| Omeprazole | Omeprazole | 279 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 78 |
| Alprazolam | Alprazolam | 230 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 65 |
| Trazodone Hcl | Trazodone Hcl | 211 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 209 | 71 |
| Gabapentin | Gabapentin | 208 | 75 |
| Pravastatin Sodium | Pravastatin Sodium | 201 | 57 |
| Metformin Hcl Er | Metformin Hcl | 197 | 65 |
| Tramadol Hcl | Tramadol Hcl | 169 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 52 |
| Simvastatin | Simvastatin | 149 | 43 |
| Carvedilol | Carvedilol | 142 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 38 |
| Bupropion Xl | Bupropion Hcl | 136 | 40 |
| Furosemide | Furosemide | 135 | 49 |
| Ozempic | Semaglutide | 132 | 34 |
| Meloxicam | Meloxicam | 131 | 47 |
| Sertraline Hcl | Sertraline Hcl | 130 | 44 |
| Alendronate Sodium | Alendronate Sodium | 128 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 37 |
| Eliquis | Apixaban | 100 | 22 |
| Famotidine | Famotidine | 100 | 39 |
| Potassium Chloride | Potassium Chloride | 100 | 27 |
| Montelukast Sodium | Montelukast Sodium | 99 | 35 |
| Metformin Hcl | Metformin Hcl | 98 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 20 |
| Valsartan | Valsartan | 76 | 21 |
| Buspirone Hcl | Buspirone Hcl | 72 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 22 |
| Celecoxib | Celecoxib | 70 | 27 |
| Allopurinol | Allopurinol | 67 | 25 |
| Valacyclovir | Valacyclovir Hcl | 66 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 19 |
| Lorazepam | Lorazepam | 61 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 22 |
| Irbesartan | Irbesartan | 59 | 18 |
| Pregabalin | Pregabalin | 59 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 17 |
| Spironolactone | Spironolactone | 56 | 19 |
| Topiramate | Topiramate | 55 | 18 |
| Jardiance | Empagliflozin | 54 | 17 |
| Ezetimibe | Ezetimibe | 53 | 19 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 51 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 17 |
| Atenolol | Atenolol | 48 | 15 |
| Finasteride | Finasteride | 47 | 17 |
| Estradiol | Estradiol | 46 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 14 |
| Ondansetron Odt | Ondansetron | 46 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 16 |
| Mounjaro | Tirzepatide | 45 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 11 |
| Farxiga | Dapagliflozin Propanediol | 43 | 13 |
| Synthroid | Levothyroxine Sodium | 43 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 16 |
| Glipizide | Glipizide | 41 | 17 |
| Januvia | Sitagliptin Phosphate | 39 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 16 |
| Mirtazapine | Mirtazapine | 38 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 35 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Diazepam | Diazepam | 33 | 12 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 13 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 29 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Prednisone | Prednisone | 27 | 22 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Naproxen | Naproxen | 24 | 11 |
| Amoxicillin | Amoxicillin | 23 | 15 |
| Azithromycin | Azithromycin | 23 | 23 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 15 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Trulance | Plecanatide | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Nisoldipine | Nisoldipine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $124.23 · 7 records | ABBVIE INC. | AREXVY, ELIQUIS, FREESTYLE LIBRE 3, INCEPTIV, NURTEC ODT, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error